Ryan Sullivan, MD
"Research is the quest for new information through the applications of rigorous methods to test relevant hypotheses. Transformative research is that research that changes the way we understand and operate in the world."
Ryan Sullivan is a clinical and translational investigator whose main areas of interest are the development of novel molecular therapeutic agents for malignant melanoma, the translation of promising preclinical findings into early stage clinical trials, and the development of predictive biomarkers for these investigational as well as standard treatment approaches. He currently serves as the Principal Investigator (PI) of a phase I clinical trials of dabrafenib, trametinib, and navitoclax in patients with advanced melanoma open at the Dana-Farber Harvard Cancer Center (DFHCC) and sponsored by the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP), a phase II clinical trial of the combination of the BRAF inhibitor vemurafenib in combination with high-dose interleukin 2, and serve as the PI on a trial exploring the utility of a novel assay to measure BRAF in the blood. Dr. Sullivan is board certified in Medical Oncology and an is a Assistant in Medicine and member of the Center for Melanoma and Teermer Center for Targeted Therapy at MGH, as well as a member of the Melanoma Program at DFHCC. He also is a member on the Dana-Farber/Harvard Cancer Center Institutional Review Board.
Dr. Sullivan is a two-time MRA-funded investigator.